Results 231 to 240 of about 10,834,928 (363)

Derivation of Particle Number Concentration from the Size Distribution: Theory and Applications. [PDF]

open access: yesAnal Chem
Farkas N   +6 more
europepmc   +1 more source

Boundary conditions and universal finite‐size scaling for the hierarchical |φ|4$|\varphi |^4$ model in dimensions 4 and higher

open access: yesCommunications on Pure and Applied Mathematics, EarlyView.
Abstract We analyse and clarify the finite‐size scaling of the weakly‐coupled hierarchical n$n$‐component |φ|4$|\varphi |^4$ model for all integers n≥1$n \ge 1$ in all dimensions d≥4$d\ge 4$, for both free and periodic boundary conditions. For d>4$d>4$, we prove that for a volume of size Rd$R^{d}$ with periodic boundary conditions the infinite‐volume ...
Emmanuel Michta   +2 more
wiley   +1 more source

"Groupitizing": A Visuo-Spatial and Arithmetic Phenomenon. [PDF]

open access: yesOpen Mind (Camb)
Maldonado Moscoso PA   +4 more
europepmc   +1 more source

Quasi‐invariance of Gaussian measures for the 3d$3d$ energy critical nonlinear Schrödinger equation

open access: yesCommunications on Pure and Applied Mathematics, EarlyView.
Abstract We consider the 3d$3d$ energy critical nonlinear Schrödinger equation with data distributed according to the Gaussian measure with covariance operator (1−Δ)−s$(1-\Delta)^{-s}$, where Δ$\Delta$ is the Laplace operator and s$s$ is sufficiently large. We prove that the flow sends full measure sets to full measure sets. We also discuss some simple
Chenmin Sun, Nikolay Tzvetkov
wiley   +1 more source

Evaluation of Potential Effects of CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Fruquintinib in Healthy Subjects

open access: yesClinical Pharmacology in Drug Development, EarlyView.
Abstract Cytochrome P450 (CYP) 3A plays a significant role in fruquintinib metabolism in vitro. This 2‐part, 2‐period fixed‐sequence study investigated the impact of CYP3A inhibition (itraconazole) and CYP3A induction (rifampin) on the pharmacokinetics (PK) of fruquintinib and M11, its main metabolite.
Martha Gonzalez   +5 more
wiley   +1 more source

Safety, Tolerability, and Pharmacokinetics of Donanemab in Healthy Chinese Participants: A Phase 1, Randomized, Double‐Blind, Placebo‐Controlled Study

open access: yesClinical Pharmacology in Drug Development, EarlyView.
Abstract Alzheimer's disease (AD), characterized by β‐amyloid (Aβ) plaques and neurofibrillary tangles, is the leading cause of dementia globally. Donanemab is a humanized immunoglobulin G1 in development as a treatment to slow AD progression. This study aimed to evaluate the safety, tolerability, pharmacokinetics (PKs), and immunogenicity of donanemab
Junyu Xu   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy